TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
TG Therapeutics has scheduled a conference call for Monday, May 5, 2025, at 8:30 AM ET to discuss their first quarter 2025 financial results and provide a business outlook for the remainder of the year. The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer.
Participants can join the call using the following dial-in numbers:
- U.S.: 1-877-407-8029
- International: 1-201-689-8029
A live webcast will be available on the Events page in the Investors & Media section of www.tgtherapeutics.com. An audio recording will remain accessible for 30 days after the call on the company website. Financial results will be released via press release before the conference call.
TG Therapeutics ha programmato una conference call per lunedì 5 maggio 2025 alle 8:30 ET per discutere i risultati finanziari del primo trimestre 2025 e fornire una panoramica aziendale per il resto dell'anno. La chiamata sarà condotta da Michael S. Weiss, Presidente e Amministratore Delegato.
I partecipanti potranno unirsi alla chiamata utilizzando i seguenti numeri di accesso:
- USA: 1-877-407-8029
- Internazionale: 1-201-689-8029
Una diretta web sarà disponibile nella pagina Eventi nella sezione Investitori & Media di www.tgtherapeutics.com. La registrazione audio resterà accessibile per 30 giorni dopo la chiamata sul sito aziendale. I risultati finanziari saranno diffusi tramite comunicato stampa prima della conference call.
TG Therapeutics ha programado una conferencia telefónica para el lunes 5 de mayo de 2025 a las 8:30 AM ET para discutir los resultados financieros del primer trimestre de 2025 y ofrecer una perspectiva comercial para el resto del año. La llamada será dirigida por Michael S. Weiss, Presidente y Director Ejecutivo.
Los participantes pueden unirse a la llamada usando los siguientes números:
- EE.UU.: 1-877-407-8029
- Internacional: 1-201-689-8029
Habrá una transmisión en vivo disponible en la página de Eventos en la sección de Inversores y Medios de www.tgtherapeutics.com. La grabación de audio estará disponible durante 30 días después de la llamada en el sitio web de la empresa. Los resultados financieros se publicarán mediante un comunicado de prensa antes de la conferencia telefónica.
TG Therapeutics는 2025년 5월 5일 월요일 오전 8시 30분(동부시간)에 2025년 1분기 재무실적과 올해 남은 기간의 사업 전망을 논의하기 위한 컨퍼런스 콜을 예정하고 있습니다. 이번 콜은 Michael S. Weiss 회장 겸 최고경영자가 주최합니다.
참석자들은 다음 전화번호로 콜에 참여할 수 있습니다:
- 미국: 1-877-407-8029
- 국제: 1-201-689-8029
라이브 웹캐스트는 www.tgtherapeutics.com의 투자자 및 미디어 섹션 내 이벤트 페이지에서 제공됩니다. 오디오 녹음은 콜 이후 30일간 회사 웹사이트에서 청취할 수 있습니다. 재무실적은 컨퍼런스 콜 전에 보도자료를 통해 공개될 예정입니다.
TG Therapeutics a programmé une conférence téléphonique pour le lundi 5 mai 2025 à 8h30 ET afin de discuter des résultats financiers du premier trimestre 2025 et de présenter les perspectives commerciales pour le reste de l'année. L'appel sera animé par Michael S. Weiss, Président et Directeur Général.
Les participants peuvent rejoindre l'appel en utilisant les numéros suivants :
- États-Unis : 1-877-407-8029
- International : 1-201-689-8029
Un webcast en direct sera disponible sur la page Événements dans la section Investisseurs & Médias de www.tgtherapeutics.com. Un enregistrement audio restera accessible pendant 30 jours après l'appel sur le site de l'entreprise. Les résultats financiers seront publiés par communiqué de presse avant la conférence téléphonique.
TG Therapeutics hat für Montag, den 5. Mai 2025, um 8:30 Uhr ET eine Telefonkonferenz angesetzt, um die Finanzergebnisse des ersten Quartals 2025 zu besprechen und einen Ausblick auf das restliche Geschäftsjahr zu geben. Die Telefonkonferenz wird von Michael S. Weiss, Vorstandsvorsitzender und Geschäftsführer, geleitet.
Teilnehmer können sich über folgende Einwahlnummern an der Konferenz beteiligen:
- USA: 1-877-407-8029
- International: 1-201-689-8029
Ein Live-Webcast ist auf der Veranstaltungsseite im Bereich Investoren & Medien unter www.tgtherapeutics.com verfügbar. Eine Audioaufzeichnung steht für 30 Tage nach der Telefonkonferenz auf der Unternehmenswebsite zur Verfügung. Die Finanzergebnisse werden vor der Telefonkonferenz per Pressemitteilung veröffentlicht.
- None.
- None.
Conference call to be held Monday, May 5, 2025, at 8:30 AM ET
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) Q1 2025 earnings call?
How can investors join TGTX's Q1 2025 earnings call?
Where can I find the replay of TGTX's Q1 2025 earnings call?
Will TGTX release Q1 2025 financial results before the earnings call?
What topics will be covered in TGTX's May 5 earnings call?
